Sensodyne Maker Haleon Leverages Eye-Level Shelf Placement To Outpace Rivals-Report
Haleon gains US market share at Walmart and Target by securing eye-level shelf placement with aggressive promotional strategies.
Read original at benzingaStocks · News reference
Why Is HUTCHMED Stock Soaring Thursday?
HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.
Read original at zacks-investment-researchCan Bixlenvo Unlock New Growth for Gilead's HIV Business?
Gilead Sciences received FDA approval for Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults unable to take current treatments. The company raised its 2026 HIV sales growth outlook to 9-10%, driven by flagship drugs Biktarvy, Descovy, and the rapidly growing Yeztugo injectable PrEP. Bixlenvo and Gilead's expanding lenacapavir pipeline offer additional growth opportunities in HIV treatment and prevention.
Read original at zacks-investment-researchSummit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday
U.S. stocks rose Thursday; Summit Therapeutics jumped 10.1% after Phase III results, while Snowflake and other stocks rallied.
Read original at benzingaHUTCHMED shares are trading higher after the company announced entered into an exclusive development and license agreement that granted the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.
Read original at benzingaWhy Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers and losers made notable moves.
Read original at benzinga